亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

A Class of Exceptionally Potent HIV-1 Protease Inhibitors

总结: Researchers at Purdue University have designed, synthesized, and evaluated a series of exceptionally potent HIV-1 protease inhibitors for the treatment of AIDS and HIV infections. These compounds represent a novel new class of HIV-1 protease inhibitors that include Tp-THF and other substituted ligands in combination with P1, P1', and P2' ligands. These compounds have demonstrated potency against wild-type viruses as well as multidrug resistant strains of HIV-1. Certain compounds exhibit nearly 100 times more potency than the current, standard HIV therapy.

技术优势: Exceptionally potent against wild-type and multidrug resistant strains of HIV-1Potency could reduce dosage requirements while maintaining efficacy

*Background: As reported by the World Health Organization (WHO), globally, there were 35.3 million people living with HIV/AIDS in 2012, a number that has been growing due to the increased availability of antiviral treatments. After peaking from 1997 to 2011, the incidence rate has declined nearly 30 percent from 3.5 million to 2.5 million, and within the last 10 years, the availability of antiretroviral therapy (ART), the combination of at least three antiretroviral (ARV) drugs, within low- and middle-income regions has increased nearly 20-fold. Despite these advances, there is still great need for novel, more powerful treatments to fight new, drug resistant strains of the disease.

*Web Links: Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry

欲了解更多信息，请点击这里